NM-3086 is under clinical development by NovelMed Therapeutics and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase II drugs for Paroxysmal Nocturnal Hemoglobinuria have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NM-3086’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NovelMed Therapeutics overview
NovelMed Therapeutics (NovelMed) is a biotechnology company. The company develops transformative therapies for the treatment of orphan and non-orphan diseases. It offers monoclonal antibodies in the therapeutic areas of paroxysmal nocturnal hemoglobinuria, age related macular degeneration, osteoarthritis, ischemia, arthritis and chronic kidney diseases, among others. NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures. It also conducts research and development for complement-mediated diseases. The company caters to patients, healthcare providers, employees, and investors across the US. NovelMed is headquartered in Cleveland, Ohio, the US.
For a complete picture of NM-3086’s drug-specific PTSR and LoA scores, buy the report here.